Multivalent Conjugation of Antibody to Dendrimers for the Enhanced Capture and Regulation on Colon Cancer Cells

• DOI: 10.1038/srep09445
• Publication Date: 2015-03-30T09:13:01Z
• Authors: Jingjing Xie; Jichuang Wang; Hongning Chen; Weiyu Shen; Patrick J. Sinko; Haiyan Dong; Rongli Zhao; Yusheng Lu; Yewei Zhu; Lee Jia
• Keywords: Dendrimers; 0303 health sciences; 03 medical and health sciences; Drug Delivery Systems; Colonic Neoplasms; Humans; Lewis X Antigen; Neoplastic Cells, Circulating; HT29 Cells; Article; Antibodies; 3. Good health

AbstractCirculation tumor cells (CTCs) in the bloodstream of early-stage cancer patients carry the important information about valuable biomarkers and biological properties of primary tumor. However, detection and capture of CTCs are challenging owing to their low concentrations. Traditional technologies have the limited detection sensitivity and the low capture efficiency. We, herein, report an effective approach to specifically bind and capture colon cancer HT29 cells by using multiple Sialyl Lewis X antibodies (aSlex)-conjugated PAMAM dendrimers. The conjugation was characterized by using atom force microscope, UV and fluorescence measurements. The capturing and regulating HT29 cells by the aSlex-coated dendrimer conjugate were analyzed by microscopy and flow cytometry. The results indicated that the conjugate showed the enhanced capture of HT29 cells in a concentration-dependent manner and the maximum capture efficiency of 77.88% was obtained within 1 h-exposure. G6-5aSlex-FITC conjugate showed capture efficiency better than FITC-G6-COOH-5aSlex conjugate. G6-5aSlex-FITC conjugate could specifically capture HT29 cells even when the target HT29 cells were diluted with the interfering cells (e.g., RBCs) to a low concentration. The capture resulted in a concentration-dependent restraint of the cell activity. In conclusion, the aSlex-coated dendrimer conjugate displayed the great potential in capturing and restraining colorectal CTCs in blood.